On March 11, the "Ganlin Programme " for early screening of people at high risk of liver cancer was held in Beijing.
Academician Zhuang Hui of Peking University Medical Department, Professor Wei Lai, Vice President of Beijing Tsinghua Chang Gung Hospital, Professor Xu Xiaoyuan of Peking University First Hospital, Professor Nan Yuemin of the Third Hospital of Hebei Medical University, Director Li Mingyang of China United Liver Health Promotion Centre, Vice President Zhu Hongbin of He Rui Genetics and other renowned liver disease experts and heads of Programme -related organisations attended the conference offline or online.
The incidence of liver cancer in China accounts for more than half of the world's population, and because there are no typical symptoms of early liver cancer, 70% of liver cancer patients are already in the middle to late stages when diagnosed, with an overall 5-year survival rate of less than 20%. Through the new liver cancer early screening technology, more people with high risk of liver cancer can have early or even very early warning of liver cancer, increasing the early diagnosis rate and reducing the mortality rate of liver cancer in China.
Li Mingyang, Director of the China Liver Health, said that the "Ganlin Programme ", which was launched on 16 December 2021, is co-sponsored by the Liver Fibrosis, Cirrhosis and Portal Hypertension Group of the Chinese Medical Association (CMA), the Liver Cancer Group of the CMA and the CLHPC. Professor Xu Xiaoyuan, Director of the Division of Liver Diseases, Chief Physician of Peking University First Hospital and Director of the China Liver Health, is leading the implementation. The Programme aims to enhance the knowledge and concept of liver cancer prevention and treatment, increase public awareness and acceptance of early screening and treatment of liver cancer, promote the practice and application of liver cancer early screening technology in clinical practice, explore the construction of a Chinese protocol for early screening of liver cancer to promote the prevention and control of liver cancer, increase the early diagnosis rate and reduce the mortality rate of liver cancer in China. Supported by Chinese Journal of Liver Diseases, Chinese Journal of Clinical Infectious Diseases, Chinese Journal of Health Management, Fujian HeRui Gene Technology Co. Professor Chen Lei from National Liver Cancer Scientific Centre/Shanghai Oriental Hepatobiliary Surgery Hospital explained the application and pathway of cfDNA whole genome sequencing-HIFI technology in early screening of liver cancer. Ms. Deng Yuanfang, the supporting organization, said that she expected the "Ganlin Programme " to involve more medical workers with screening concepts, knowledge and experience in liver cancer prevention and control through activities such as hospital academic exchanges, case collection competitions and community clinics, and to jointly contribute to the prevention and control of liver cancer in China. Zhuang Hui, Chen Lei, Chen Yu, Duan Xuezhang, Fu Junliang, Ji Dong, Jia Jidong, Li Jia, Nan Yuemin, Tian Yu, Wei Lai, Xie Wen, Xing Huichun, Xu Xiaoyuan, Yu Yanyan, Zhu Hongbin, He Ying, Deng Yuanfang, Li Mingyang, Wang Fengjiao and other experts, agency/Programme leaders and representatives from public interest organizations participated in the discussion. Professor Wei Lai delivered a speech on behalf of the Programme organizers, and Academician Zhuang Hui gave the conference summary. Professor Jia Jidong, Professor Xie Wen, Professor Duan Xuezhang, Professor Xu Xiaoyuan and Director Li Mingyang chaired the relevant exchange sessions. |
关注官方微信 
